3/29/2013

Data from the Nationwide Inpatient Sample show more stroke patients treated at certified primary stroke centers got intravenous recombinant tissue plasminogen activator therapy compared with patients treated at other hospitals, University of Pennsylvania researchers reported in the Journal of the American Heart Association. Use of tPA increased at both certified and noncertified centers during the study period, however, researchers said.

Related Summaries